© 1995 Oxford University Press
RESEARCH-ARTICLE |
Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice
1Departments of Human Genetics, University of Michigan Medical School Ann Arbor, Michigan 48109-0618, USA 2Physiology and Institute for Gerontology, University of Michigan Medical School Ann Arbor, Michigan 48109-0618, USA 3Human Genome Center, University of Michigan Medical School Ann Arbor, Michigan 48109-0618, USA
*To whom correspondence should be addressed
Received February 17, 1995; Revised May 3, 1995; Accepted May 3, 1995
Duchenne and Becker muscular dystrophy are caused by defects in the dystrophin gene, and are candidates for treatment by gene therapy. We have shown previously that overexpression of a full-length dystrophin cDNA prevents the development of dystrophic symptoms in mdx mice. We show here that this functional correction can be achieved by expressing the full-length muscle isoform at a lower level than is present in control animals. Gene therapy for DMD may necessitate the use of truncated dystrophin mini-genes to accommodate the limited cloning capacity of current-generation viral delivery vectors. We have constructed both murine and human mini-genes deleted for exons 17–48, and have demonstrated that expression of either mini-gene can almost completely prevent the development of dystrophic symptoms in transgenic mdx mice. These results suggest that viral-mediated expression of moderate levels of a truncated dystrophin could be an effective treatment for DMD.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Yang, X. Liu, J. Yu, L. Sheng, Y. Shi, Z. Li, Y. Hu, J. Xue, L. Wu, Y. Liang, et al. A non-viral vector for potential DMD gene therapy study by targeting a minidystrophin-GFP fusion gene into the hrDNA locus Acta Biochim Biophys Sin, September 28, 2009; (2009) gmp080v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Li, Y. Yue, and D. Duan Preservation of Muscle Force in Mdx3cv Mice Correlates with Low-Level Expression of a Near Full-Length Dystrophin Protein Am. J. Pathol., May 1, 2008; 172(5): 1332 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Adams, Y. Tesch, J. M. Percival, D. E. Albrecht, J. I. Conhaim, K. Anderson, and S. C. Froehner Differential targeting of nNOS and AQP4 to dystrophin-deficient sarcolemma by membrane-directed {alpha}-dystrobrevin J. Cell Sci., January 1, 2008; 121(1): 48 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Banks, P. Gregorevic, J. M. Allen, E. E. Finn, and J. S. Chamberlain Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain Hum. Mol. Genet., September 1, 2007; 16(17): 2105 - 2113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Duan Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R253 - R261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. N. Rybakova, J. L. Humston, K. J. Sonnemann, and J. M. Ervasti Dystrophin and Utrophin Bind Actin through Distinct Modes of Contact J. Biol. Chem., April 14, 2006; 281(15): 9996 - 10001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Abedi, D. A. Greer, B. M. Foster, G. A. Colvin, J. A. Harpel, D. A. Demers, J. Pimentel, M. S. Dooner, and P. J. Quesenberry Critical variables in the conversion of marrow cells to skeletal muscle Blood, August 15, 2005; 106(4): 1488 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Chakkalakal, J. Thompson, R. J. Parks, and B. J. Jasmin Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies FASEB J, June 1, 2005; 19(8): 880 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bertoni, G. E. Morris, and T. A. Rando Strand bias in oligonucleotide-mediated dystrophin gene editing Hum. Mol. Genet., January 15, 2005; 14(2): 221 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Burkin, G. Q. Wallace, D. J. Milner, E. J. Chaney, J. A. Mulligan, and S. J. Kaufman Transgenic Expression of {alpha}7{beta}1 Integrin Maintains Muscle Integrity, Increases Regenerative Capacity, Promotes Hypertrophy, and Reduces Cardiomyopathy in Dystrophic Mice Am. J. Pathol., January 1, 2005; 166(1): 253 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Dell'Agnola, Z. Wang, R. Storb, S. J. Tapscott, C. S. Kuhr, S. D. Hauschka, R. S. Lee, G. E. Sale, E. Zellmer, S. Gisburne, et al. Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs Blood, December 15, 2004; 104(13): 4311 - 4318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matecki, R. W. R. Dudley, M. Divangahi, R. Gilbert, J. Nalbantoglu, G. Karpati, and B. J. Petrof Therapeutic gene transfer to dystrophic diaphragm by an adenoviral vector deleted of all viral genes Am J Physiol Lung Cell Mol Physiol, September 1, 2004; 287(3): L569 - L576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yue, J. W. Skimming, M. Liu, T. Strawn, and D. Duan Full-length dystrophin expression in half of the heart cells ameliorates {beta}-isoproterenol-induced cardiomyopathy in mdx mice Hum. Mol. Genet., August 1, 2004; 13(15): 1669 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Chamberlain Gene therapy of muscular dystrophy Hum. Mol. Genet., October 1, 2002; 11(20): 2355 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. DelloRusso, J. M. Scott, D. Hartigan-O'Connor, G. Salvatori, C. Barjot, A. S. Robinson, R. W. Crawford, S. V. Brooks, and J. S. Chamberlain Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin PNAS, October 1, 2002; 99(20): 12979 - 12984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Q. Harper, R. W. Crawford, C. DelloRusso, and J. S. Chamberlain Spectrin-like repeats from dystrophin and {alpha}-actinin-2 are not functionally interchangeable Hum. Mol. Genet., August 1, 2002; 11(16): 1807 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. CROSBIE, S. A. DOVICO, J. D. FLANAGAN, J. S. CHAMBERLAIN, C. L. OWNBY, and K. P. CAMPBELL Characterization of aquaporin-4 in muscle and muscular dystrophy FASEB J, July 1, 2002; 16(9): 943 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Warner, C. DelloRusso, R. W. Crawford, I. N. Rybakova, J. R. Patel, J. M. Ervasti, and J. S. Chamberlain Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy Hum. Mol. Genet., May 1, 2002; 11(9): 1095 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. N. Rybakova, J. R. Patel, K. E. Davies, P. D. Yurchenco, and J. M. Ervasti Utrophin Binds Laterally along Actin Filaments and Can Couple Costameric Actin with Sarcolemma When Overexpressed in Dystrophin-deficient Muscle Mol. Biol. Cell, May 1, 2002; 13(5): 1512 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Fabb, D. J. Wells, P. Serpente, and G. Dickson Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice Hum. Mol. Genet., April 1, 2002; 11(7): 733 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Blake, A. Weir, S. E. Newey, and K. E. Davies Function and Genetics of Dystrophin and Dystrophin-Related Proteins in Muscle Physiol Rev, April 1, 2002; 82(2): 291 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kohrer, L. Xie, S. Kellerer, U. Varshney, and U. L. RajBhandary Import of amber and ochre suppressor tRNAs into mammalian cells: A general approach to site-specific insertion of amino acid analogues into proteins PNAS, November 15, 2001; (2001) 251438898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Crawford, Q. L. Lu, T. A. Partridge, and J. S. Chamberlain Suppression of revertant fibers in mdx mice by expression of a functional dystrophin Hum. Mol. Genet., November 1, 2001; 10(24): 2745 - 2750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Allamand and K. P. Campbell Animal models for muscular dystrophy: valuable tools for the development of therapies Hum. Mol. Genet., October 1, 2000; 9(16): 2459 - 2467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ahmad, M. Brinson, B.L. Hodges, J.S. Chamberlain, and A. Amalfitano Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy Hum. Mol. Genet., October 1, 2000; 9(17): 2507 - 2515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Rafael, E. R. Townsend, S. E. Squire, A. C. Potter, J. S. Chamberlain, and K. E. Davies Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure Hum. Mol. Genet., May 22, 2000; 9(9): 1357 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xiao, J. Li, Y.-P. Tsao, D. Dressman, E. P. Hoffman, and J. F. Watchko Full Functional Rescue of a Complete Muscle (TA) in Dystrophic Hamsters by Adeno-Associated Virus Vector-Directed Gene Therapy J. Virol., February 1, 2000; 74(3): 1436 - 1442. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. H. Crosbie, C. S. Lebakken, K. H. Holt, D. P. Venzke, V. Straub, J. C. Lee, R. M. Grady, J. S. Chamberlain, J. R. Sanes, and K. P. Campbell Membrane Targeting and Stabilization of Sarcospan Is Mediated by the Sarcoglycan Subcomplex J. Cell Biol., April 5, 1999; 145(1): 153 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Straub, J. A. Rafael, J. S. Chamberlain, and K. P. Campbell Animal Models for Muscular Dystrophy Show Different Patterns of Sarcolemmal Disruption J. Cell Biol., October 20, 1997; 139(2): 375 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kohrer, L. Xie, S. Kellerer, U. Varshney, and U. L. RajBhandary Import of amber and ochre suppressor tRNAs into mammalian cells: A general approach to site-specific insertion of amino acid analogues into proteins PNAS, December 4, 2001; 98(25): 14310 - 14315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Ostedgaard, J. Zabner, D. W. Vermeer, T. Rokhlina, P. H. Karp, A. A. Stecenko, C. Randak, and M. J. Welsh CFTR with a partially deleted R domain corrects the cystic fibrosis chloride transport defect in human airway epithelia in vitro and in mouse nasal mucosa in vivo PNAS, March 5, 2002; 99(5): 3093 - 3098. [Abstract] [Full Text] [PDF]
|
|